Fragment Length of Circulating Tumor DNA

Malignant tumors shed DNA into the circulation. The transient half-life of circulating tumor DNA (ctDNA) may afford the opportunity to diagnose, monitor recurrence, and evaluate response to therapy solely through a non-invasive blood draw. However, detecting ctDNA against the normally occurring back...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	PLoS genetics Ročník 12; číslo 7; s. e1006162
Hlavní autoři:	Underhill, Hunter R., Kitzman, Jacob O., Hellwig, Sabine, Welker, Noah C., Daza, Riza, Baker, Daniel N., Gligorich, Keith M., Rostomily, Robert C., Bronner, Mary P., Shendure, Jay
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Public Library of Science 01.07.2016 Public Library of Science (PLoS)
Témata:	Alleles Animals Biology and life sciences Biomarkers, Tumor - blood Carcinoma, Hepatocellular - genetics Carcinoma, Hepatocellular - metabolism Cell Line, Tumor Deoxyribonucleic acid DNA DNA sequencing DNA, Neoplasm - blood DNA, Neoplasm - genetics Experiments Genes Genetic aspects Glioblastoma - blood Glioblastoma - genetics Hep G2 Cells Humans Liver Neoplasms - genetics Liver Neoplasms - metabolism Lung cancer Lung Neoplasms - genetics Lung Neoplasms - metabolism Magnetic Resonance Imaging Male Medicine and Health Sciences Melanoma Melanoma - genetics Melanoma - metabolism Metastasis Methods Mutation Neoplasm Transplantation Proto-Oncogene Proteins B-raf - genetics Rats Research and Analysis Methods Studies Tumors
ISSN:	1553-7404, 1553-7390, 1553-7404
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Malignant tumors shed DNA into the circulation. The transient half-life of circulating tumor DNA (ctDNA) may afford the opportunity to diagnose, monitor recurrence, and evaluate response to therapy solely through a non-invasive blood draw. However, detecting ctDNA against the normally occurring background of cell-free DNA derived from healthy cells has proven challenging, particularly in non-metastatic solid tumors. In this study, distinct differences in fragment length size between ctDNAs and normal cell-free DNA are defined. Human ctDNA in rat plasma derived from human glioblastoma multiforme stem-like cells in the rat brain and human hepatocellular carcinoma in the rat flank were found to have a shorter principal fragment length than the background rat cell-free DNA (134-144 bp vs. 167 bp, respectively). Subsequently, a similar shift in the fragment length of ctDNA in humans with melanoma and lung cancer was identified compared to healthy controls. Comparison of fragment lengths from cell-free DNA between a melanoma patient and healthy controls found that the BRAF V600E mutant allele occurred more commonly at a shorter fragment length than the fragment length of the wild-type allele (132-145 bp vs. 165 bp, respectively). Moreover, size-selecting for shorter cell-free DNA fragment lengths substantially increased the EGFR T790M mutant allele frequency in human lung cancer. These findings provide compelling evidence that experimental or bioinformatic isolation of a specific subset of fragment lengths from cell-free DNA may improve detection of ctDNA.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Conceived and designed the experiments: HRU JOK SH NCW KMG RCR MPB JS. Performed the experiments: HRU JOK SH NCW RD DNB KMG. Analyzed the data: HRU JOK SH NCW RD DNB KMG MPB RCR JS. Contributed reagents/materials/analysis tools: HRU JOK SH DNB KMG RCR MPB JS. Wrote the paper: HRU JOK SH NCW RD DNB KMG RCR MPB JS. The authors have declared that no competing interests exist.
ISSN:	1553-7404 1553-7390 1553-7404
DOI:	10.1371/journal.pgen.1006162